 |
Top 10 Heart disease treatment startups in USA
Updated: May 13, 2024 |
1
Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
2
Funding: $1.2B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
3
Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
4
Funding: $390.6M
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
5
Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
6
Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
7
Funding: $282.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
8
Funding: $280.5M
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
9
Funding: $167M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
10
Funding: $154.3M
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
Ad
Advertise your startup
11
Funding: $145M
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
12
Funding: $138.2M
Cutting-edge technology that empowers employees to improve heart health.
Cutting-edge technology that empowers employees to improve heart health.
13
Funding: $129.7M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
14
Funding: $128.2M
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
15
Funding: $115M
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
16
Funding: $102M
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
17
Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
18
Funding: $96.2M
CircuLite is a cardiovascular device company, focused on developing minimally-invasive micro-pumps to treat chronic heart failures.
CircuLite is a cardiovascular device company, focused on developing minimally-invasive micro-pumps to treat chronic heart failures.
19
Funding: $39.4M
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
20
Funding: $77.9M
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
21
Funding: $56.3M
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
22
Funding: $53M
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
23
Funding: $39.6M
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
24
Funding: $35.5M
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
25
Funding: $31.6M
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
26
Funding: $28.5M
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
27
Funding: $17.5M
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
28
Funding: $10.7M
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
29
Funding: $14.1M
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
30
Funding: $12.5M
Vector is a cardiac digital health provider that makes it simple for care teams to capture, manage, analyze, and act on remote cardiac data.
Vector is a cardiac digital health provider that makes it simple for care teams to capture, manage, analyze, and act on remote cardiac data.
31
Funding: $11M
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
32
Angionetics is focused on the late-stage clinical development and commercialization of Generx, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
33
Funding: $8M
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
34
Funding: $8M
CardioOne is a physician-centric partner that helps independent cardiology practices reach their full potential.
CardioOne is a physician-centric partner that helps independent cardiology practices reach their full potential.
35
Funding: $8M
Chamber Cardio is a healthcare platform enhances cardiovascular health services.
Chamber Cardio is a healthcare platform enhances cardiovascular health services.
37
Funding: $4.7M
Vixiar Medical develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases.
Vixiar Medical develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases.
38
Funding: $3.5M
Dyad Medical develops software that automatically analyzes the content of cardiac and cardiovascular images.
Dyad Medical develops software that automatically analyzes the content of cardiac and cardiovascular images.
39
Funding: $2M
Sentinel leverages data from wearable blood pressure devices to improve care and outcomes for people with high blood pressure.
Sentinel leverages data from wearable blood pressure devices to improve care and outcomes for people with high blood pressure.
40
OtiTopic's mission is to provide patients with a faster alternative for management of suspected myocardial infarction (MI).